Chimerix (NASDAQ:CMRX): The mean estimate for the short term price target for Chimerix (NASDAQ:CMRX) stands at $8.38 according to 8 Analysts. The higher price target estimate for the stock has been calculated at $15 while the lower price target estimate is at $5.
Company shares have received an average consensus rating of Hold for the current week
On the companys insider trading activities, Mario Ernest, director of Chimerix Inc, had purchased 10,000 shares on May 13, 2016. The total value of the transaction was $45,300. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Chimerix (NASDAQ:CMRX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.2 points or 4.83% at $3.94 with 1,263,846 shares getting traded. Post opening the session at $4.12, the shares hit an intraday low of $3.87 and an intraday high of $4.141 and the price was in this range throughout the day. The company has a market cap of $182 million and the number of outstanding shares have been calculated to be 46,213,134 shares. The 52-week high of Chimerix (NASDAQ:CMRX) is $58.04 and the 52-week low is $3.87.
Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).